MétaCan
Menu
Back to cohort
Record W3115855235 · doi:10.2337/dc20-1675

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

2020· article· en· W3115855235 on OpenAlexafffund
Silvio E. Inzucchi, Kieran F. Docherty, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Scott D. Solomon, Subodh Verma, Jan Bělohlávek, Michael Böhm, Chern‐En Chiang, Rudolf A. de Boer, Mirta Díez, Andre Dukát, Charlotta Ljungman, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, Pardeep S. Jhund, John J.V. McMurray

Bibliographic record

VenueDiabetes Care · 2020
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoSt. Michael's Hospital
FundersNational Institutes of HealthVifor PharmaDeutsche ForschungsgemeinschaftCytokineticsEisaiUniversity of OxfordZora BiosciencesKidney Research UKHLS TherapeuticsIFM TherapeuticsMedicines CompanyAmerican Heart AssociationIntarcia TherapeuticsIronwood Pharmaceuticals, IncorporatedEsperion TherapeuticsAlnylam PharmaceuticalsNovo NordiskMyoKardiaDaiichi Sankyo EuropeServierGilead SciencesBritish Heart FoundationBrigham and Women's HospitalEli Lilly and CompanyAstraZenecaSanofi PasteurCelladon CorporationPfizerAmgenSanofiDefense Acquisition Program AdministrationAmerican Diabetes Association
KeywordsDapagliflozinMedicineEjection fractionHeart failureDiabetes mellitusInternal medicineType 2 diabetesIncidence (geometry)CardiologyBenzhydryl compoundsType 1 diabetesEndocrinology

Abstract

fetched live from OpenAlex

OBJECTIVE The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial. RESEARCH DESIGN AND METHODS The subgroup of 2,605 patients with heart failure and reduced ejection fraction (HFrEF), no prior history of diabetes, and an HbA1c of <6.5% at baseline was randomized to dapagliflozin 10 mg daily or placebo. In this exploratory analysis, surveillance for new-onset diabetes was accomplished through periodic HbA1c testing as part of the study protocol and comparison between the treatment groups assessed through a Cox proportional hazards model. RESULTS At baseline, the mean HbA1c was 5.8%. At 8 months, there were minimal changes, with a placebo-adjusted change in the dapagliflozin group of −0.04%. Over a median follow-up of 18 months, diabetes developed in 93 of 1,307 patients (7.1%) in the placebo group and 64 of 1,298 (4.9%) in the dapagliflozin group. Dapagliflozin led to a 32% reduction in diabetes incidence (hazard ratio 0.68, 95% CI 0.50–0.94; P = 0.019). More than 95% of the participants who developed T2D had prediabetes at baseline (HbA1c 5.7–6.4%). Participants who developed diabetes in DAPA-HF had a higher subsequent mortality than those who did not. CONCLUSIONS In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.009
Threshold uncertainty score0.420

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.217
Teacher spread0.208 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations76
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueDiabetes CareSame topicDiabetes Treatment and ManagementFrench-language works237,207